Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,001–2,100 of 15,747
Yazaki, S., Yoshida, T., Kojima, Y., Yagishita, S., Nakahama, H., Okinaka, K., Matsushita, H., Shiotsuka, M., Kobayashi, O., Iwata, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2159 · Cited by 56
Munitz, A., Yechezkel, M., Dickstein, Y., Yamin, D., & Gerlic, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100264 · Cited by 58
Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
McMillan, C. L. D., Choo, J. J. Y., Idris, A., Supramaniam, A., Modhiran, N., Amarilla, A. A., Isaacs, A., Cheung, S. T. M., Liang, B., Bielefeldt‐Ohmann, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj8065 · Cited by 57
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
Ma, M. T., Badeti, S., Chen, C.-H., Kim, J., Choudhary, A. K., Honnen, B., Reichman, C., Calianese, D. C., Pinter, A., Jiang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652223 · Cited by 55
Ultrasonic particles: An approach for targeted gene delivery
Walsh, A. P. G., Gordon, H. N., Peter, K., & Wang, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113998 · Cited by 59
Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54
Park, J. K., Lee, E. B., Shin, K., Sung, Y., Kim, T., Kwon, S., Lee, M. S., Hong, S., Choi, B. Y., Lee, S., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e95 · Cited by 56
Huang, A., Cicin‐Sain, C., Pasin, C., Epp, S., Audigé, A., Mueller, N. J., Nilsson, J., Bankova, A. K., Wolfensberger, N., Vilinovszki, O., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.019 · Cited by 58
“%) received BNT162b, and only 15% received mRNA-1273.”
BackgroundInfluentialKorosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Gholami, S., Ghaemi, M. S., Moyles, I. R., Craig, M., Ooi, H. K., & Heffernan, J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-25134-0 · Cited by 63
An Overview of the Use of Nanoparticles in Vaccine Development
Lozano, D., Larraga, V., Vallet‐Regí, M., & Manzano, M. (2023) · Nanomaterials · doi:10.3390/nano13121828 · Cited by 66
“Two months later, in May 2020, Phase I results were published, and then, 6 months later, Phase II and III results were presented, with 94–95% effectiveness (as a reference, the flu vaccine should be around 45% effective), in what was a giant victory for science and for nanoparticle technology [100,101].”
BackgroundPardieck, I. N., van der Sluis, T. C., van der Gracht, E. T. I., Veerkamp, D. M. B., Behr, F. M., van Duikeren, S., Beyrend, G., Rip, J., Nadafi, R., Nejad, E. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31721-6 · Cited by 62
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change
Fülöp, T., Larbi, A., Pawelec, G., Cohen, A. A., Provost, G., Khalil, A., Lacombe, G., Rodrigues, S., Desroches, M., Hirokawa, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10040607 · Cited by 61
Ripabelli, G., Tamburro, M., Buccieri, N., Adesso, C., Caggiano, V., Cannizzaro, F., Palma, M. A. D., Mantuano, G., Montemitro, V. G., Natale, A., et al. (2021) · Journal of Community Health · doi:10.1007/s10900-021-01039-3 · Cited by 62
Abokalawa, F., Ahmad, S. F., Hassan, A. M., Alexander, K. J., Al-Hashel, J. Y., & Arabi, M. R. (2021) · Seizure · doi:10.1016/j.seizure.2021.08.001 · Cited by 58
“[20] In a large UK community study, a lower incidence of fatigue (15%) was identified following the BNT162b2 second dose.”
InfluentialGlatman-Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y., & Keinan-Boker, L. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103574 · Cited by 53
“This estimation is of particular importance since the oldest age group ( 75 years old), was substantially smaller than other age groups in the vaccine efficacy study conducted by the manufacturer [5].”
InfluentialBuonfrate, D., Piubelli, C., Gobbi, F. G., Martini, D., Bertoli, G., Ursini, T., Moro, L., Ronzoni, N., Angheben, A., Rodari, P., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.024 · Cited by 53
“Overall, AE were more frequent than was reported in the phase 2/3 randomized clinical trial assessing efficacy and safety of the BNT162b2 vaccine [16] and other cohort studies [17,18].”
BackgroundAbu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Tang, P., Al Kanaani, Z., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003879 · Cited by 54
“Qatar also launched a mass coronavirus disease 2019 (COVID-19) immunization campaign on 21 December 2020, using the BNT162b2 (Pfizer–BioNTech) [5] and mRNA-1273 (Moderna) [6] vaccines, but vaccine coverage was limited before the end of March 2021 [7–9].”
MethodTakano, T., Morikawa, M., Adachi, Y., Kabasawa, K., Sax, N., Moriyama, S., Sun, L., Isogawa, M., Nishiyama, A., Onodera, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100631 · Cited by 62
“The criteria used for the clinical trial of the BNT162b2 mRNA vaccine were applied.(1) Local 3 symptom severity scores and systemic 8 symptom severity scores were summed for the total local symptom severity grades and total systemic symptom severity grades, respectively.”
InfluentialInnate and adaptive immune responses toward nanomedicines
Viana, I. M. D. O., Roussel, S., Defrêne, J., Lima, E. M., Barabé, F., & Bertrand, N. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.022 · Cited by 63
Liew, T. M., & Lee, C. S. (2021) · JMIR Public Health and Surveillance · doi:10.2196/29789 · Cited by 60
Han, T., Ma, S., Sun, C., Zhang, H., Qu, G., Chen, Y., Cheng, C., Chen, E. L., Ahmed, M. A., Kim, K. Y., et al. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.08.002 · Cited by 59
Clinical progress of nanomedicine-based RNA therapies
Lim, S. A., Cox, A., Tung, M., & Chung, E. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.018 · Cited by 73
Sing, C., Tang, C. T.-L., Chui, C. S. L., Fan, M., Lai, F. T. T., Li, X., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., Hung, I. F., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26478 · Cited by 63
B Cell Response to Vaccination
Luo, W., & Yin, Q. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1903033 · Cited by 63
Lee, M., & You, M. (2021) · Journal of Medical Internet Research · doi:10.2196/32329 · Cited by 63
“These results are similar to the findings of the clinical trial [50].”
ResultType 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine
Özdemir, İ. H., Özlek, B., Özen, M. B., Gündüz, R., & Bayturan, Ö. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.04.018 · Cited by 59
Opportunities and challenges for T cell-based influenza vaccines
Mosmann, T. R., McMichael, A. J., LeVert, A., McCauley, J. W., & Almond, J. W. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01030-8 · Cited by 57
“39,40).”
Haskin, O., Ashkenazi‐Hoffnung, L., Ziv, N., Borovitz, Y., Dagan, A., Levi, S. S., Koren, G., Hamdani, G., Erez, D. L., Landau, D., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003922 · Cited by 52
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 64
Levine, A. C., Fukuta, Y., Huaman, M. A., Ou, J., Meisenberg, B. R., Patel, B., Paxton, J. H., Hanley, D. F., Rijnders, B. J. A., Gharbharan, A., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad088 · Cited by 54
“Meanwhile, mAbs to prevent hospitalization [8, 9] and vaccines [10, 11] to prevent symptomatic infection, hospitalization, or death were not available until December 2020.”
Self-citationRen, Y., Lin, L., Abdallah, M., Zhu, X., Liu, H., Fabb, S. A., Payne, T. J., Pouton, C. W., Johnston, A. P. R., & Trevaskis, N. L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113945 · Cited by 70
Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA
Vlatkovic, I., Ludwig, J., Boros, G., Szabó, G. T., Reichert, J., Buff, M. C. R., Baiersdörfer, M., Reinholz, J., Mahiny, A. J., Şahin, U., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020328 · Cited by 59
Self-citationSoegiarto, G., Wulandari, L., Purnomosari, D., Fahmita, K. D., Gautama, H. I., Hadmoko, S. T., Prasetyo, M. E., Mahdi, B. A., Arafah, N., Prasetyaningtyas, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.059 · Cited by 67
“These include adenovirus-based vaccines [3–5], mRNA vaccines [6,7] and inactivated viral vaccines [8–11].”
BackgroundCanti, L., Humblet‐Baron, S., Desombere, I., Neumann, J., Pannus, P., Heyndríckx, L., Henry, A., Servais, S., Willems, É., Ehx, G., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01190-3 · Cited by 57
“Clinical studies demonstrated that Pfizer/BioNTech BNT162b2 vaccine provided 95% protection in healthy adults after injection of two doses of vaccine given three weeks apart [9].”
BackgroundKorzun, T., Moses, A. S., Jozić, A., Grigoriev, V., Newton, S., Kim, J., Diba, P., Sattler, A. L., Levasseur, P. R., Le, N., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05088 · Cited by 67
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 57
Correlates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 61
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
Stephens, L. M., & Varga, S. M. (2021) · Vaccines · doi:10.3390/vaccines9060624 · Cited by 55
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 60
von Wrede, R. D., Pukropski, J., Moskau‐Hartmann, S., Surges, R., & Baumgartner, T. R. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108160 · Cited by 53
Signals of hope: gauging the impact of a rapid national vaccination campaign
Shilo, S., Rossman, H., & Segal, E. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00531-0 · Cited by 54
Lombardi, A., Butta, G. M., Donnici, L., Bozzi, G., Oggioni, M., Bono, P., Matera, M., Consonni, D., Ludovisi, S., Muscatello, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100287 · Cited by 53
Chivese, T., Matizanadzo, J. T., Musa, O. A. H., Hindy, G., Furuya‐Kanamori, L., Islam, N., Al-Shebly, R., Shalaby, R., Habibullah, M., Al-Marwani, T. A., et al. (2022) · Pathogens and Global Health · doi:10.1080/20477724.2022.2029301 · Cited by 56
“Despite the availability of several efficacious and safe vaccines against COVID-19 (1, 2), access to the vaccines is limited, especially for low and middle-income countries (LMICs) (3).”
BackgroundAnanworanich, J., Lee, I. T., Ensz, D. J., Carmona, L., Schaefers, K., Avanesov, A. S., Stadlbauer, D., Choi, A., Pucci, A., McGrath, S. M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae329 · Cited by 66
Yan, V. K. C., Wan, E. Y. F., Ye, X., Mok, A. H. Y., Lai, F. T. T., Chui, C. S. L., Li, X., Wong, C. K. H., Li, P. H., Ma, T., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2114854 · Cited by 53
Self-citationCalcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies
Berlansky, S., Sallinger, M., Grabmayr, H., Humer, C., Bernhard, A., Fahrner, M., & Frischauf, I. (2022) · Cells · doi:10.3390/cells11020253 · Cited by 53
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
Meyer, R. A., Hussmann, G. P., Peterson, N. C., Santos, J. L., & Tuesca, A. D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121314 · Cited by 57
Ossato, A., Tessari, R., Trabucchi, C., Zuppini, T., Realdon, N., & Marchesini, F. (2021) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-002933 · Cited by 58
Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 55
“While a large-scale study has revealed high and comparable efficacy of the BNT162b2 mRNA COVID-19 vaccine in young and older adults (Polack et al., 2020), at least in the short term, there are limited data available for those in the 8 and higher decades of life (Hyams et al.”
BackgroundNano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery
Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 61
Zakarya, K. D., Бекболатович, К. Л., Orynbayev, M. B., Abduraimov, Y. O., Sultankulova, K. T., Kassenov, M. M., Sarsenbayeva, G., Кулмагамбетов, И. Р., Davlyatshin, T. I., Sergeeva, M. V., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101078 · Cited by 61
“Amongst the first vaccines, several vector-based (Gamaleya National Research Centre [4], University of Oxford/AstraZeneca [5]) and mRNA-based vaccines (Moderna/ National Institute of Allergy and Infectious Diseases [6], BioNTech/ Fosun Pharma/Pfizer [7]) have been developed and produced.”
BackgroundDendrimer-Mediated Delivery of DNA and RNA Vaccines
Kisakova, L. A., Apartsin, E. K., Nizolenko, L. F., & Карпенко, Л. И. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041106 · Cited by 55
“The first mRNA-based vaccines against infectious diseases, developed by Moderna and Pfizer/BioNTech, have been approved for human vaccination against COVID-19 in 2020 [3,4].”
BackgroundRusso, G., Lai, Q., Poli, L., Perrone, M. P., Gaeta, A., Rossi, M., Mastroianni, C. M., Garofalo, M., & Pretagostini, R. (2021) · Clinical Transplantation · doi:10.1111/ctr.14495 · Cited by 51
Ioannou, G. N., Locke, E. R., Green, P. K., & Berry, K. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101326 · Cited by 58
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 60
Almofti, Y. A., Abd-elrahman, K. A., & Eltilib, E. E. M. (2021) · BMC Immunology · doi:10.1186/s12865-021-00412-0 · Cited by 61
The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development
Sun, C., Chen, X., Kang, Y., & Zeng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677027 · Cited by 59
Rapid characterization of spike variants via mammalian cell surface display
Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 56
Jain, L., Vij, J., Satapathy, P., Chakrapani, V., Patro, B. K., Kar, S. S., Singh, R., Pala, S., Sankhe, L., Modi, B., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.735902 · Cited by 59
“However, at the time of the study, acceptance of these vaccines remained skeptical, with safety (10) and efficacy (11) as major concerns.”
BackgroundPang, A. P. S., Higgins‐Chen, A., Comite, F., Raica, I., Arboleda, C., Went, H., Mendez, T. L., Schotsaert, M., Dwaraka, V. B., Smith, R. C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.819749 · Cited by 76
“The developed mRNA vaccines for COVID-19 have been shown to elicit a potent humoral immune response and be highly efficacious at preventing COVID-19 and severe disease outcomes (Polack et al., 2020; Baden et al., 2021; Tartof et al., 2021).”
BackgroundSeirafianpour, F., Pourriyahi, H., Mesgarha, M. G., Mohammad, A. P., Shaka, Z., & Goodarzi, A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15461 · Cited by 51
The Power of Field-Flow Fractionation in Characterization of Nanoparticles in Drug Delivery
Bian, J., Gobalasingham, N. S., Purchel, A. A., & Lin, J. (2023) · Molecules · doi:10.3390/molecules28104169 · Cited by 58
“It became more widely known in late 2020 because some COVID-19 vaccines, notably mRNA-1273 [87] and BNT162b [88], used PEGylated-lipid nanoparticles for mRNA delivery [89].”
BackgroundAli, G. G. M. N., Rahman, M. M., Hossain, M. A., Rahman, M. S., Paul, K. C., Thill, J., & Samuel, J. (2021) · Healthcare · doi:10.3390/healthcare9091110 · Cited by 56
“1% efficacy, respectively, in clinical trials [7,8]).”
Grieco, T., Maddalena, P., Sernicola, A., Muharremi, R., Basili, S., Alvaro, D., Cangemi, R., Rossi, A., & Pellacani, G. (2021) · Dermatologic Therapy · doi:10.1111/dth.15153 · Cited by 52
“The first COVID-19 vaccine, ComirnatyTM, was granted conditional marketing approval (CMA) on December 21, 2020.(1) Authorization for SpikevaxTM (previously COVID-19 Vaccine Moderna), for VaxzevriaTM (previously COVID-19 Vaccine AstraZeneca) and for COVID-19 Vaccine Janssen followed on Received: 23 August 2021 Revised:…”
BackgroundSARS-CoV-2 subunit vaccine adjuvants and their signaling pathways
Mekonnen, D. S., Mengist, H. M., & Jin, T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1991794 · Cited by 58
Wang, W.-C., Sayedahmed, E. E., & Mittal, S. K. (2022) · Viruses · doi:10.3390/v14122727 · Cited by 58
“During the COVID-19 pandemic, second-generation vaccine platforms such as AdV vectorbased and mRNA-based vaccines were developed [6,7].”
BackgroundPolymeric materials for immune engineering: Molecular interaction to biomaterial design
Soni, S. S., & Rodell, C. B. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.016 · Cited by 54
Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 64
Recent progress in application of nanovaccines for enhancing mucosal immune responses
Du, G., Qin, M., & Sun, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.010 · Cited by 58
Zerbo, O., Ray, G. T., FIREMAN, B. H., Layefsky, E., Goddard, K., Lewis, E. M., Ross, P., Omer, S. B., Greenberg, M., & Klein, N. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36547-4 · Cited by 56
Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts
Aran, D. (2021) · medRxiv · doi:10.1101/2021.02.05.21251139 · Cited by 50
Miyashita, Y., Yoshida, T., Takagi, Y., Tsukamoto, H., Takashima, K., Kouwaki, T., Makino, K., Fukushima, S., Nakamura, K., & Oshiumi, H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00439-3 · Cited by 53
Huang, C., Duan, X., Wang, J., Tian, Q., Ren, Y., Chen, K., Zhang, Z., Li, Y., Feng, Y., Zhong, K., et al. (2022) · Advanced Science · doi:10.1002/advs.202205532 · Cited by 63
Biomaterial‐based gene therapy
Yu, Y., Gao, Y., He, L., Fang, B., Ge, W., Pu, Y., Ju, Y., Xie, X., & Lei, L. (2023) · MedComm · doi:10.1002/mco2.259 · Cited by 65
Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis
Murali, M., Gumber, L., Jethwa, H., Ganesh, D., Hartmann‐Boyce, J., Sood, H. S., Zaccardi, F., & Khunti, K. (2023) · BMC Medicine · doi:10.1186/s12916-023-02809-7 · Cited by 60
“Landmark trials have provided compelling evidence for several vaccines such as BNT162b2 messenger ribonucleic acid (mRNA) [12], ChAdOx1 nCoV-19 (AZD1222) [13] and mRNA-1273 [14], and therapies including dexamethasone [15] and sotrovimab [16].”
BackgroundAntigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
Kraft, J. C., Pham, M. N., Shehata, L., Brinkkemper, M., Boyoglu-Barnum, S., Sprouse, K. R., Walls, A. C., Cheng, S., Murphy, M., Pettie, D., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100780 · Cited by 63
Göbel, C. H., Heinze, A., Karstedt, S. C., Morscheck, M., Tashiro, L., Cirkel, A., Hamid, Q. A., Halwani, R., Temsah, M.-H. A., Ziemann, M., et al. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00296-3 · Cited by 57
COVID-19 vaccine acceptance and hesitancy among primary healthcare workers in Singapore
Koh, S. W. C., Liow, Y., Loh, V. W. K., Liew, S. J., Chan, Y., & Young, D. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01693-z · Cited by 57
“in reducing risk of infection and severe disease [2, 3].”
BackgroundSafety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
Bahrani, S. A., Albarrak, A. M., Alghamdi, O. A., Alghamdi, M. A., Hakami, F. H., Abaadi, A. K. A., Alkhrashi, S. A., Alghamdi, M. Y., Almershad, M. M., Alanazi, M. M., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.052 · Cited by 55
Yaniv, K., Ozer, E., Lewis, Y. E., & Kushmaro, A. (2021) · Water Research · doi:10.1016/j.watres.2021.117808 · Cited by 57
Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates
Buckley, M., Araínga, M., Maiorino, L., Pires, I. S., Kim, B., Michaels, K. K., Dye, J., Qureshi, K., Zhang, Y. J., Mak, H. H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.008 · Cited by 66
Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery
Sanchez, A. J. D. S., Zhao, K., Huayamares, S. G., Hatit, M. Z. C., Lokugamage, M. P., Loughrey, D., Dobrowolski, C. N., Wang, S., Kim, H., Paunovska, K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.037 · Cited by 55
Mechanisms of antibody-dependent enhancement of infectious disease
Wells, T. J., Esposito, T., Henderson, I. R., & Labzin, L. I. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01067-9 · Cited by 71
Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination
Cognetti, J. S., & Miller, B. L. (2021) · Sensors · doi:10.3390/s21175857 · Cited by 53
“While our calibration data were derived from commercial S1 + S2 ECD protein, the protein produced in vivo following BNT162b2 vaccination was prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein [1].”
BackgroundMethodInfluentialZhang, Z., Guo, L., Huang, L., Zhang, C., Luo, R., Zeng, L., Liang, H., Li, Q., Lü, X., Wang, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1911 · Cited by 58
Lee, S. W., Moon, J., Lee, S.-K., Lee, H. J., Moon, S., Chung, S. J., Yeo, Y., Park, T. S., Park, D. W., Kim, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.779212 · Cited by 53
“Clinical trials of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273 COVID-19 vaccines) showed similar efficacy between people with or without obesity (2, 3).”
BackgroundO'Shea, D. G., Curtin, C. M., & O’Brien, F. J. (2022) · Biomaterials Science · doi:10.1039/d1bm01540k · Cited by 65
Gill, L. A., & Jones, C. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004367 · Cited by 51
Coronavirus disease 2019 (COVID‐19) vaccines: A concise review
Samaranayake, L. P., Seneviratne, C. J., & Fakhruddin, K. S. (2021) · Oral Diseases · doi:10.1111/odi.13916 · Cited by 53
Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
Karim, S. S. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00468-2 · Cited by 52
Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
Ghimire, D., Han, Y., & Lu, M. (2022) · Viruses · doi:10.3390/v14061255 · Cited by 45
Revon‐Rivière, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A. C., de Lamballerie, X. N., & André, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.002 · Cited by 52
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins
Eweje, F., Ibrahim, V., Shajii, A., Walsh, M. L., Ahmad, K., Alrefai, A., Miyasato, D. L., Davis, J. R., Ham, H. O., Li, K., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02664-2 · Cited by 67
He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 77
“According to published clinical data, Comirnaty® has high protection and safety, which two-dose regimen provides 95% COVID-19 protection for people 16 years of age and older [113].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.